BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/12/2023 8:10:41 AM | Browse: 218 | Download: 497
 |
Received |
|
2022-10-15 14:39 |
|
Peer-Review Started |
|
2022-10-15 14:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-11-02 14:09 |
|
Revised |
|
2022-11-11 11:48 |
|
Second Decision |
|
2023-03-13 03:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-03-16 05:41 |
|
Articles in Press |
|
2023-03-16 05:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-03-07 03:20 |
|
Typeset the Manuscript |
|
2023-04-06 04:40 |
|
Publish the Manuscript Online |
|
2023-04-12 08:10 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Recent advances in targeted therapy for pancreatic adenocarcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Ting Fang, Wen-Wei Yang, Ya-Ru Niu and Yong-Kun Sun |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Research and Development Program of China |
2021YFF1201300 |
| The Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research |
320.6750.2022-10-95 |
|
| Corresponding Author |
Yong-Kun Sun, MD, Professor, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Pan-jia-yuan South Lane, Chaoyang District, Beijing 100021, China. hsunyk@cicams.ac.cn |
| Key Words |
Pancreatic carcinoma; Targeted therapy; Cancer stem cell; Monoclonal antibody; Epigenetic modifier |
| Core Tip |
Pancreatic adenocarcinoma (PDAC) is a fatal and rare disease with a 5-year survival rate of 8% and a median survival of 6 mo. In PDAC, targeted therapy has been extensively evaluated; however, survival improvement of this aggressive disease using a targeted strategy has been minimal. This manuscript summarizes current targeted therapies and clinical trials targeting dysregulated signaling pathways and components of the PDAC oncogenic process, analyzes possible reasons for the lack of positive results in clinical trials, and suggests ways to improve them. We also discuss emerging trends in targeted therapies for PDAC: combining targeted inhibitors of multiple pathways. |
| Publish Date |
2023-04-12 08:10 |
| Citation |
Fang YT, Yang WW, Niu YR, Sun YK. Recent advances in targeted therapy for pancreatic adenocarcinoma. World J Gastrointest Oncol 2023;15(4): 571-595 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i4/571.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i4.571 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
